Topic starter
There is a new scientific article that investigates how lifelong use of various psychedelics is associated with the severity of opioid use disorder.
In it, we discuss:
The authors used data from the 2023 US National Survey on Drug Use and Health, containing information from 45,133 adults. They examined not only opioid-related issues but also mental health, as psychological complaints often coexist with more severe forms of opioid use disorder.
The real focus of this article lies on the difference between types of psychedelics. In their analyses, mescaline and peyote formed one group, while LSD, psilocybin, MDMA, and DMT fell into another group. That distinction proved important because both patterns were associated with the severity of opioid use disorder in very different ways.
The results were striking. Use in the mescaline/peyote group was associated with a lower severity of opioid use disorder, whereas use in the LSD/psilocybin/MDMA/DMT group was associated with a higher severity. Additionally, mental health problems were independently associated with more severe opioid issues.
It also appeared that mental health altered the associations. The association between mescaline or peyote and lower severity of opioid use disorder was particularly evident in people with more mental impairments. The unfavorable association for the other psychedelics persisted, but was slightly less strong in that group.
It is important to note, however, that this is an observational, cross-sectional study. This means that this article does not prove that mescaline or peyote protect against opioid addiction, nor does it prove that LSD, psilocybin, MDMA, or DMT increase its severity. The study only shows associations, and the authors emphasize that context, intention of use, and other explanations need to be investigated further.
In one sentence: this article shows that lifelong psychedelic use should not be viewed as a single category, because different substances are associated very differently with the severity of opioid use disorder.
Spoiler
New article description
Abstract
Background: Opioid use disorder (OUD) remains a major public health crisis in the United States, with mental health disorders substantially increasing risk severity. Emerging evidence suggests psychedelics may relate to reduced OUD risk. This exploratory study examined associations between lifetime psychedelic use and OUD severity and tested whether these associations varied by mental health impairment.
Methods: Structural equation modeling of the cross-sectional 2023 US National Survey on Drug Use and Health with multiple-group moderation (n = 45,133 adults). OLD severity was the primary outcome. Independent variables were two psychedelic factors derived from factor analysis: mescaline/peyote (Psychedelic_F1) and LSD/psilocybin/MDMA/DMT (Psychedelic_F2). Mental health impairment was modeled as a latent construct and used to define high vs. low impairment groups. Covariates included age, sex, and income.
Findings: Psychedelic_F1 associated with lower OUD severity (β = -0.34, p = 0.001), whereas Psychedelic_F2 associated with higher severity (β = 0.60, p < 0.001). Mental health impairment positively associated with OUD severity (β = 0.21, p < 0.001). Moderation analyzes indicated Psychedelic_F1 related to lower OUD severity only in the high mental health impairment group (β = -0.15, p = 0.041), while the positive association for Psychedelic_F2 was attenuated among those with high impairment (β = 0.38, p < 0.001, vs. β = 0.48, p = 0.004).
Conclusions: Psychedelic use patterns showed divergent associations with OUD severity. Mescaline/peyote use was linked to lower severity, whereas LSD/psilocybin/MDMA/DMT use was linked to higher severity, with effects differing by mental health impairment. Contextual and motivational factors underlying psychedelic use warrant further investigation.
Keywords: Opioid use disorder; psychedelics; mescaline; peyote; psilocybin; LSD; MDMA; DMT; mental health impairment; national survey.
Posted : 18 March 2026 14:33